Mrsa Treatment | MRSA Treatment Company ImmuVen Raising Money For Pre-IND Meeting


An Illinois company developing a way to stop superbugs like MRSA is raising capital that would take it into earliest stages of the drug approval process.

ImmuVen is developing a line of T cell receptor-related drugs . At first, the treatment will focus on infectious viral diseases such as methicillin-resistant Staphylococcus aureus (MRSA), which ImmuVen says it can halt by stopping the toxins secreted by MRSA. But the company also thinks that it can go beyond superbugs and use its technology to fight cancer.


The University of Illinois spinoff disclosed in a recent SEC filing that it had raised $250,000 and could continue to raise an unspecified amount of money. “Financially, we’re in the middle of a


Click here to view rest of article from original site

New Quinolones With Potential Anti-mrsa Activity (cancer Etiology, Diagnosis And New Quinolones With Potential Anti-mrsa Activity (cancer Etiology, Diagnosis And
reatments)
Buy now $49.00
Vetericyn All Animal Hydrogel Spray, 16-ounce Trigger Vetericyn All Animal Hydrogel Spray, 16-ounce Trigger

Buy new $40.00 $36.19



Facebook Twitter Email